```
### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ******** HHHHHHHH SSSSSSSS?
### Status: Signing onto Dialog
 ********
ENTER PASSWORD:
 ******** HHHHHHHH SSSSSSSS? ********
Welcome to DIALOG
### Status: Connected


Dialog level 02.12.60D

Last logoff:  04apr03 15:47:13
Logon file001 13apr03 14:54:17
           *** ANNOUNCEMENT ***
                    ***
--File 515 D&B Dun's Electronic Business Directory is now online
completely updated and redesigned. For details, see HELP NEWS 515.
                    ***
--File 990 - NewsRoom now contains October 2002 to present records.
File 993 - NewsRoom archive contains 2002 records from January 2002-
September 2002. To search all 2002 records, BEGIN 990,993 or B NEWS2002
                    ***
--Alerts have been enhanced to allow a single Alert profile to be
stored and run against multiple files. Duplicate removal is available
across files and for up to 12 months. The Alert may be run according
to the file's update frequency or according to a custom
calendar-based schedule. There are no additional prices for these
enhanced features. See HELP ALERT for more information.
                    ***
--U.S. Patents Fulltext (File 654) has been redesigned with
new search and display features.  See HELP NEWS 654 for
information.
                    ***
--Connect Time joins DialUnits as pricing options on Dialog.
See HELP CONNECT for information.
                    ***
--CLAIMS/US Patents (Files 340,341, 942) have been enhanced
with both application and grant publication level in a
single record. See HELP NEWS 340 for information.
                    ***
--SourceOne patents are now delivered to your email inbox
as PDF replacing TIFF delivery. See HELP SOURCE1 for more
information.
                    ***
--Important news for public and academic
libraries.  See HELP LIBRARY for more information.
                    ***
--Important Notice to Freelance Authors--
See HELP FREELANCE for more information
                    ***
For information about the access to file 43 please see Help News43.
***
NEW FILES RELEASED
***Dialog NewsRoom - Current 3-4 months (File 990)
***Dialog NewsRoom - 2002 Archive (File 993)
***Dialog NewsRoom - 2001 Archive (File 994)
***Dialog NewsRoom - 2000 Archive (File 995)
***TRADEMARKSCAN-Finland (File 679)
```

```
***TRADEMARKSCAN-Norway    ile 678)
***TRADEMARKSCAN-Sweden  (File 675)
                  ***
UPDATING RESUMED
***Delphes European Business (File 481)
                  ***
RELOADED
***D&B Dun's Electronic Business Directory (File 515)
***U.S. Patents Fulltext 1976-current (File 654)
***Population Demographics (File 581)
***Kompass Western Europe (File 590)
***D&B - Dun's Market Identifiers  (File 516)

REMOVED
***Chicago Tribune (File 632)
***Fort Lauderdale Sun Sentinel (File 497)
***The Orlando Sentinel (File 705)
***Newport News Daily Press (File 747)
***U.S. Patents Fulltext 1980-1989 (File 653)
***TOXNET data is added to ToxFile (F156)

***New document supplier***
IMED has been changed to INFOTRIE (see HELP OINFOTRI)


     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                  ****
KWIC is set to 50.
HILIGHT set on as '*'
* * * *

File   1:ERIC  1966-2003/Mar 24
       (c) format only 2003 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?b 155, 159, 5, 73
       13apr03 14:54:33 User259876 Session D486.1
            $0.33    0.095 DialUnits File1
     $0.33  Estimated cost File1
     $0.06  TELNET
     $0.39  Estimated cost this search
     $0.39  Estimated total session cost   0.095 DialUnits


SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R)  1966-2003/Apr W1
        (c) format only 2003 The Dialog Corp.
*File 155: Medline has been reloaded and accession numbers have
changed.  Please see HELP NEWS 155.
  File 159:Cancerlit  1975-2002/Oct
        (c) format only 2002 Dialog Corporation
*File 159: Cancerlit ceases updating with immediate effect.
Please see HELP NEWS.
  File   5:Biosis Previews(R)  1969-2003/Apr W1
        (c) 2003 BIOSIS
*File   5: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File  73:EMBASE  1974-2003/Apr W1
        (c) 2003 Elsevier Science B.V.
*File  73: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.

      Set  Items  Description
```

```
      ---  -----  ------   --
?s (PPAR (w) gamma) (s) (osteosarcoma or ovarian or renal or SAOS-2)
            5509  PPAR
          666429  GAMMA
           43016  OSTEOSARCOMA
          254508  OVARIAN
          864079  RENAL
               1  SAOS-2
      S1      44  (PPAR (W) GAMMA) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL OR
                  SAOS-2)
?s s1 not py>1997
              44  S1
         7979165  PY>1997
      S2       2  S1 NOT PY>1997
?rd
...completed examining records
      S3       1  RD (unique items)
?t s3/3,k/all

 3/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

08409996   95098011   PMID: 7799943
  PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate
carboxykinase gene.
  Tontonoz P; Hu E; Devine J; Beale E G; Spiegelman B M
  Dana-Farber Cancer Institute, Boston, Massachusetts 02115.
  Molecular and cellular biology (UNITED STATES)  Jan 1995, 15  (1)
 p351-7, ISSN 0270-7306  Journal Code: 8109087
  Contract/Grant No.: DK31405; DK; NIDDK; T32 GM07753; GM; NIGMS; T32
HD07271; HD; NICHD; +
  Document type: Journal Article
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: Completed

  ... of a chloramphenicol acetyltransferase gene from a heterologous
promoter in cultured 3T3-F442A preadipocytes and adipocytes. We further
demonstrate that the adipocyte-specific transcription factor *PPAR* *gamma*
2, previously identified as a regulator of the adipocyte P2 enhancer, binds
in a heterodimeric complex with RXR alpha to the PEPCK 5'-flanking region
at two sites, termed PCK1 (bp -451 to -439) and PCK2 (bp -999 to -987).
Forced expression of *PPAR* *gamma* 2 and RXR alpha activates the PEPCK
enhancer in non-adipose cells. This activation is potentiated by peroxisome
proliferators and fatty acids but not by 9-cis retinoic acid. Mutation of
the *PPAR* *gamma* 2 binding site (PCK2) abolishes both the activity of the
enhancer in adipocytes and its ability to be activated by *PPAR* *gamma* 2
and RXR alpha. These results establish a role for *PPAR* *gamma* 2 in the
adipose expression of the PEPCK gene and suggest that this factor functions
as a coordinate regulator of multiple adipocyte-specific genes.
?ds

Set     Items   Description
S1         44   (PPAR (W) GAMMA) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL OR -
              SAOS-2)
S2          2   S1 NOT PY>1997
S3          1   RD (unique items)
?s (troglitazone or pioglitazone or rosiglitazone or thiazolidinedione) (s) (osteosarco
ma or ovarian or renal or SAOS-2)
            4673  TROGLITAZONE
            2120  PIOGLITAZONE
            2210  ROSIGLITAZONE
            2873  THIAZOLIDINEDIONE
           43016  OSTEOSARCOMA
          254508  OVARIAN
```

```
          864079  RENAL
               1  SAOS-2
      S4     224  (TROGLITAZONE OR PIOGLITAZONE OR ROSIGLITAZONE OR
                  THIAZOLIDINEDIONE) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL
                  OR SAOS-2)
?s s4 not py>1997
             224  S4
         7979165  PY>1997
      S5      13  S4 NOT PY>1997
?rd
...completed examining records
      S6       6  RD (unique items)
?t s6/3,k/all
```

6/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

11075019 97430108 PMID: 9284429

[Treatment of hypertension associated with diabetes mellitus]

Katayama S
Fourth Department of Medicine, Saitama Medical School.

Nippon rinsho. Japanese journal of clinical medicine (JAPAN) Aug 1997, 55 (8) p2091-6, ISSN 0047-1852 Journal Code: 0420546
Document type: Journal Article; Review; Review, Tutorial ; English Abstract
Languages: JAPANESE
Main Citation Owner: NLM
Record type: Completed

... more than a half of diabetics are hypertensive. Therefore, it is very important to treat hypertension to reduce cardiovascular events as well as end-stage *renal* disease. At first, life style modification such as body weight reduction, exercise and restriction of salt and alcohol intake will be recommended. Improved glycemic control by such a non-pharmacological therapy will lower blood pressure. Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and *troglitazone* reduce blood pressure. If these maneuvers do not lower blood pressure, hypotensive medication will be necessary. As a first line therapy, ACE inhibitor, alpha 1...

6/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

11017776 97371217 PMID: 9227442

Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.

Yoshimoto T; Naruse M; Nishikawa M; Naruse K; Tanabe A; Seki T; Imaki T; Demura R; Aikawa E; Demura H
Department of Medicine, Tokyo Women's Medical College, Japan.

American journal of physiology (UNITED STATES) Jun 1997, 272 (6 Pt 1) pE989-96, ISSN 0002-9513 Journal Code: 0370511
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... has been shown to be a new therapeutic approach for treating diabetes mellitus, details of effects of this treatment on the cardiovascular system and possible *renal* complications remain unknown. In the present study, we investigated the effects of a thiazolidine derivative, *pioglitazone*, and examined the insulin-sensitizing action on blood pressure, nephropathy, and vascular changes in genetically obese diabetic Wistar fatty (WF) rats. *Pioglitazone* (3 mg.kg-1.day-1) was orally administered for 13 wk starting

at the age of 5 wk, and results were compared with...
... treated WF rats. At the age of 18 wk, vehicle-treated WF rats were associated with mild hypertension, nephropathy with proteinuria histological glomerular injury, and *renal* arteriolosclerosis in addition to hyperglycemia, hyperinsulinemia, and hyperlipidemia. Treatment with *pioglitazone* significantly improved glucose and lipid metabolism. In addition, it lowered blood pressure, decreased proteinuria, and prevented glomerular injury, *renal* arteriolosclerosis, and aortic medial wall thickening, whereas body weight, food intake, sodium balance, and urinary norepinephrine excretion were significantly increased. These results suggest that the insulin-sensitizing agent *pioglitazone* is effective in correcting not only glucose and lipid metabolism but also cardiovascular and *renal* complications in non-insulin-dependent diabetes mellitus.

6/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

11004846 97358160 PMID: 9215280

***Troglitazone* improves defects in insulin action, insulin secretion, *ovarian* steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.**

Ehrmann D A; Schneider D J; Sobel B E; Cavaghan M K; Imperial J; Rosenfield R L; Polonsky K S
Department of Medicine, University of Chicago, Illinois 60637, USA.

Journal of clinical endocrinology and metabolism (UNITED STATES) Jul 1997, 82 (7) p2108-16, ISSN 0021-972X Journal Code: 0375362
Contract/Grant No.: DK-02315; DK; NIDDK; DK-20595; DK; NIDDK; DK-31842; DK; NIDDK; +
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

***Troglitazone* improves defects in insulin action, insulin secretion, *ovarian* steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.**

Women with polycystic ovary syndrome (PCOS) are characterized by defects in insulin action, insulin secretion, *ovarian* steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent *troglitazone* to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects. All subjects had oligomenorrhea, hirsutism, polycystic ovaries, and hyperandrogenemia. Before and after treatment with *troglitazone* (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently...

...vs. 381 +/- 96; P < 0.05). The ability of the beta-cell to appropriately detect and respond to an oscillatory glucose infusion improved significantly after *troglitazone* treatment; the normalized spectral power for the insulin secretion rate increased to 5.9 +/- 1.1 from 4.3 +/- 0.8 (P < 0.05). Basal...

... ng/dL; P < 0.05) and free testosterone (33.3 +/- 4.0 vs. 21.2 +/- 2.6 pg/mL; P < 0.01) declined significantly after *troglitazone* treatment. Leuprolide-stimulated levels of 17-hydroxyprogesterone, androstenedione, and total testosterone were significantly lower posttreatment compared to pretreatment. The reduction in androgen levels occurred independently...

... 05). The marked reduction in PAI-1 could be expected to improve the fibrinolytic response to thrombosis in these subjects. We conclude that administration of *troglitazone* to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. *Troglitazone* holds potential as a useful primary or adjunctive treatment for women with PCOS.

6/3,K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

07991160 94056877 PMID: 8238439
***Pioglitazone* attenuates hypertension and inhibits growth of *renal* arteriolar smooth muscle in rats.**
Dubey R K; Zhang H Y; Reddy S R; Boegehold M A; Kotchen T A
Department of Medicine, School of Medicine, West Virginia University, Morgantown 26506.
American journal of physiology (UNITED STATES) Oct 1993, 265 (4 Pt 2) pR726-32, ISSN 0002-9513 Journal Code: 0370511
Contract/Grant No.: HL-23312; HL; NHLBI; HL-37753; HL; NHLBI; HL-44012; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

***Pioglitazone* attenuates hypertension and inhibits growth of *renal* arteriolar smooth muscle in rats.**
Hypertension is frequently associated with insulin resistance. We evaluated the effects of *pioglitazone*, an agent that increases insulin sensitivity, on the development of hypertension in the Dahl salt-sensitive (Dahl-S) rat and in the one-kidney, one-clip Sprague-Dawley rat. We also evaluated the effects of *pioglitazone* on growth of cultured preglomerular *renal* arteriolar smooth muscle cells. In Dahl-S rats fed a 3% NaCl diet, tail systolic blood pressures and direct arterial pressures were lower ($P < 0.05$) in *pioglitazone*-treated (20 mg/kg daily by gavage for 3 wk) than in control rats ($n = 10$ rats/group). In one-kidney, one-clip Sprague-Dawley rats, systolic blood pressures were also lower in *pioglitazone*-treated animals ($P < 0.0001$). In vitro, proliferation of arteriolar smooth muscle cells was stimulated ($P < 0.01$) by insulin, epidermal growth factor (EGF), and fetal calf serum (FCS); *pioglitazone* (5 microM) reversibly inhibited ($P < 0.01$) insulin-, EGF-, and FCS-induced proliferation. *Pioglitazone* (0.01-100 microM) also inhibited insulin- (1 mU/ml), EGF- (100 ng/ml), and 5% FCS-induced [3H]thymidine incorporation in a concentration-dependent manner ($P < 0.01$). Thus *pioglitazone* attenuated the development of hypertension in the Dahl-S rat and the one-kidney, one-clip rat. The ability of *pioglitazone* to inhibit growth of vascular smooth muscle may contribute to its hypotensive effect.

6/3,K/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

07010090 EMBASE No: 1997296799
Nephropathy in genetically obese-diabetic Wistar fatty rats - Characterization and prevention
Suzuki M.; Yamada Y.; Yamasaki H.; Anayama H.; Sasaki S.; Odaka H.; Ikeda H.
M. Suzuki, Pharmaceutical Research Lab. II, Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Osaka Japan
Japanese Pharmacology and Therapeutics (JPN. PHARMACOL. THER.) (Japan) 1997, 25/2 (43-51)
CODEN: YACHD ISSN: 0386-3603
DOCUMENT TYPE: Journal; Article
LANGUAGE: JAPANESE SUMMARY LANGUAGE: ENGLISH; JAPANESE
NUMBER OF REFERENCES: 24

...those in male Wistar fatty rats. Hyperglycemic male Wistar fatty rats showed the most advanced nephropathy among these fatty rats. Male Wistar fatty rats showed *renal* lesions such as the expansion of the glomerular

mesangial area, slight thickening of the glomerular capillary basement membrane and formation of hyaline casts and atrophy of the *renal* tubules. When *pioglitazone*, an insulin-sensitizing agent, was orally administered (3.0 mg/kg/day) to male Wistar fatty rats for 12 weeks beginning at 5 weeks of age, hyperglycemia did not develop throughout the experiment, and the age-dependent increase in plasma triglyceride and insulin were markedly suppressed. *Pioglitazone* significantly suppressed urinary albumin, protein and NAG excretion as well as the development of *renal* glomerular lesions. These results suggest that the manifestation of nephropathy in NIDDM is closely related to the development of hyperglycemia.

6/3,K/6 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

06913069 EMBASE No: 1997197511
Insulin and lipid metabolism: New developments in drug therapy
Mackay A.J.; Petrie J.R.
J.R. Petrie, Dept. of Medicine/Therapeutics, Western Infirmary, Glasgow G11 6NT United Kingdom
Expert Opinion on Investigational Drugs (EXPERT OPIN. INVEST. DRUGS) (United Kingdom) 1997, 6/6 (665-675)
CODEN: EOIDE ISSN: 1354-3784
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 84

...approach which has the potential not only to treat, but also to prevent NIDDM in high-risk individuals. The most promising new agents are the *thiazolidinedione* derivatives, in particular *troglitazone*. Thiazolidinediones are ligands for a specific subtype of the peroxisome proliferator activated receptor (PPAR), and decrease plasma glucose levels in both obesity and NIDDM, while...

...reviewed, along with an assessment of their potential in the prevention and treatment of diverse pathophysiological states characterised by insulin resistance, including atherosclerosis and polycystic *ovarian* disease. Reference is made to the current status of other experimental agents including hydantoin derivatives, betainf 3-adrenoceptor agonists, and inhibitors of lipolysis.

```
?ds

Set     Items   Description
S1         44   (PPAR (W) GAMMA) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL OR -
               SAOS-2)
S2          2   S1 NOT PY>1997
S3          1   RD (unique items)
S4        224   (TROGLITAZONE OR PIOGLITAZONE OR ROSIGLITAZONE OR THIAZOLI-
               DINEDIONE) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL OR SAOS-2)
S5         13   S4 NOT PY>1997
S6          6   RD (unique items)
?s s4 and (cancer or tumor or tumour or neoplastic)
             224  S4
         2236483  CANCER
         2112670  TUMOR
          270004  TUMOUR
          579420  NEOPLASTIC
      S7      28  S4 AND (CANCER OR TUMOR OR TUMOUR OR NEOPLASTIC)
?rd
...completed examining records
      S8      12  RD (unique items)
?s s8 not py>1999
             12  S8
        5022972  PY>1999
      S9       1  S8 NOT PY>1999
```

?t s9/3,k/all

9/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11413018 BIOSIS NO.: 199800194350
Inhibition of cell proliferation in Saos-2 human *osteosarcoma* cells by *troglitazone*.
AUTHOR: Copland J; Gasic S; Soloff M
AUTHOR ADDRESS: Univ. Texas Med. Branch, Galveston, TX 77555**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 39p69-70 March, 1998
CONFERENCE/MEETING: 89th Annual Meeting of the American Association for Cancer Research New Orleans, Louisiana, USA March 28-April 1, 1998
SPONSOR: American Association for Cancer Research
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English

Inhibition of cell proliferation in Saos-2 human *osteosarcoma* cells by *troglitazone*.
...MAJOR CONCEPTS: *Tumor* Biology
?ds

Set	Items	Description
S1	44	(PPAR (W) GAMMA) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL OR SAOS-2)
S2	2	S1 NOT PY>1997
S3	1	RD (unique items)
S4	224	(TROGLITAZONE OR PIOGLITAZONE OR ROSIGLITAZONE OR THIAZOLIDINEDIONE) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL OR SAOS-2)
S5	13	S4 NOT PY>1997
S6	6	RD (unique items)
S7	28	S4 AND (CANCER OR TUMOR OR TUMOUR OR NEOPLASTIC)
S8	12	RD (unique items)
S9	1	S8 NOT PY>1999

?rd s1
...completed examining records
S10 27 RD S1 (unique items)
?s s10 not py>1999
27 S10
5022972 PY>1999
S11 3 S10 NOT PY>1999
?t s11/3,k/all

11/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

11482984 98366895 PMID: 9703335
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Buckingham R E; Al-Barazanji K A; Toseland C D; Slaughter M; Connor S C; West A; Bond B; Turner N C; Clapham J C
SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK.
Diabetes (UNITED STATES) Aug 1998, 47 (8) p1326-34, ISSN 0012-1797 Journal Code: 0372763
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Rosiglitazone (BRL 49653), a peroxisome proliferator-activated receptor-gamma (*PPAR*-*gamma*) agonist and potent insulin action-enhancing

agent, was given in the diet (50 micromol/kg of diet) to male Zucker rats ages 6-7 weeks...

...had become established (4 months; ages 24-25 weeks). In either treatment mode, rosiglitazone normalized urinary N-acetyl-beta-D-glucosaminidase activity, a marker for *renal* proximal tubular damage, and ameliorated the rise in systolic blood pressure that occurred coincidentally with the development of proteinuria in Zucker fatty control rats. The *renal* protective action of rosiglitazone was verified morphologically. Thus in the prevention group there was an absence of the various indexes of chronic nephropathy that were...

... treatment. These data demonstrate that treatment of Zucker fatty rats with rosiglitazone produced substantial protection over a prolonged period against the development and progression of *renal* injury and the adaptive changes to pancreatic islet morphology caused by sustained hyperinsulinemia.

11/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

08409996 95098011 PMID: 7799943
PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene.
Tontonoz P; Hu E; Devine J; Beale E G; Spiegelman B M
Dana-Farber Cancer Institute, Boston, Massachusetts 02115.
Molecular and cellular biology (UNITED STATES) Jan 1995, 15 (1) p351-7, ISSN 0270-7306 Journal Code: 8109087
Contract/Grant No.: DK31405; DK; NIDDK; T32 GM07753; GM; NIGMS; T32 HD07271; HD; NICHD; +
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... of a chloramphenicol acetyltransferase gene from a heterologous promoter in cultured 3T3-F442A preadipocytes and adipocytes. We further demonstrate that the adipocyte-specific transcription factor *PPAR* *gamma* 2, previously identified as a regulator of the adipocyte P2 enhancer, binds in a heterodimeric complex with RXR alpha to the PEPCK 5'-flanking region at two sites, termed PCK1 (bp -451 to -439) and PCK2 (bp -999 to -987). Forced expression of *PPAR* *gamma* 2 and RXR alpha activates the PEPCK enhancer in non-adipose cells. This activation is potentiated by peroxisome proliferators and fatty acids but not by 9-cis retinoic acid. Mutation of the *PPAR* *gamma* 2 binding site (PCK2) abolishes both the activity of the enhancer in adipocytes and its ability to be activated by *PPAR* *gamma* 2 and RXR alpha. These results establish a role for *PPAR* *gamma* 2 in the adipose expression of the PEPCK gene and suggest that this factor functions as a coordinate regulator of multiple adipocyte-specific genes.

11/3,K/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

07885930 EMBASE No: 1999342021
Rosiglitazone: A new therapy for Type 2 diabetes
Greene D.A.
D.A. Greene, Internal Medicine Department, Michigan Diabetes Res. Training Ctr., Univ. of Michigan Medical School, Ann Arbor, MI 48109-0611 United States
Expert Opinion on Investigational Drugs (EXPERT OPIN. INVEST. DRUGS) (United Kingdom) 1999, 8/10 (1709-1719)
CODEN: EOIDE ISSN: 1354-3784

DOCUMENT TYPE: Journal [redacted]eview
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 38

...2 diabetes. As with other thiazolidinediones, it binds to the gamma-isoform of the peroxisome proliferator-activated receptor (PPAR), a nuclear hormone receptor. Subsequent to *PPAR*-*gamma* activation rosiglitazone increases insulin suppression of hepatic glucose output and increases peripheral glucose uptake in the muscles, thereby improving the glycaemic state of the individual...

...target organs responsible for the condition, namely the liver, pancreas, skeletal muscle and adipose tissue. These studies also suggest that rosiglitazone may help in preserving *renal* and pancreatic function that deteriorates in chronic hyperinsulinaemia. In clinical studies, rosiglitazone has been shown to be effective. safe and well-tolerated, not only when...
?ds

Set	Items	Description
S1	44	(PPAR (W) GAMMA) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL OR SAOS-2)
S2	2	S1 NOT PY>1997
S3	1	RD (unique items)
S4	224	(TROGLITAZONE OR PIOGLITAZONE OR ROSIGLITAZONE OR THIAZOLIDINEDIONE) (S) (OSTEOSARCOMA OR OVARIAN OR RENAL OR SAOS-2)
S5	13	S4 NOT PY>1997
S6	6	RD (unique items)
S7	28	S4 AND (CANCER OR TUMOR OR TUMOUR OR NEOPLASTIC)
S8	12	RD (unique items)
S9	1	S8 NOT PY>1999
S10	27	RD S1 (unique items)
S11	3	S10 NOT PY>1999

?logoff
13apr03 15:06:32 User259876 Session D486.2
$2.67 0.835 DialUnits File155
$1.47 7 Type(s) in Format 3
$1.47 7 Types
$4.14 Estimated cost File155
$0.77 0.262 DialUnits File159
$0.77 Estimated cost File159
$4.23 0.755 DialUnits File5
$1.75 1 Type(s) in Format 3
$1.75 1 Types
$5.98 Estimated cost File5
$6.76 0.751 DialUnits File73
$7.50 3 Type(s) in Format 3
$7.50 3 Types
$14.26 Estimated cost File73
OneSearch, 4 files, 2.603 DialUnits FileOS
$2.80 TELNET
$27.95 Estimated cost this search
$28.34 Estimated total session cost 2.698 DialUnits

Status: Signed Off. (13 minutes)